Literature DB >> 17438665

Pediatric HIV infection: diagnostic laboratory methods.

Jorge Lujan-Zilbermann1, Carina A Rodriguez, Patricia J Emmanuel.   

Abstract

The diagnosis of HIV-1 infection in infants and children continues to present challenges. Currently available virologic assays are sensitive and specific and allow early detection of perinatally acquired HIV infection. Identification soon after birth allows for the rapid initiation of antiretroviral therapy and preservation of the infant's immune system. Serologic diagnostic methods, including HIV-ELISA, Western blot, and immunofluorescence Assay can be used to make the diagnosis of HIV infection in infants older than 18 months of age, children, and adolescents. Recently developed rapid tests allow for testing outside clinical sites, provide results in a short period of time, and allow for prompt initiation of effective prophylaxis in cases of exposure particularly maternal to child transmission. We discuss here the diagnostic management of HIV-exposed infants and HIV-infected children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17438665     DOI: 10.1080/15513810601123367

Source DB:  PubMed          Journal:  Fetal Pediatr Pathol        ISSN: 1551-3815            Impact factor:   0.958


  3 in total

1.  Impact of HIV/Aids on Child Mortality before the Highly Active Antiretroviral Therapy Era: A Study in Pointe-Noire, Republic of Congo.

Authors:  Camille Lallemant; Gaston Halembokaka; Gaelle Baty; Nicole Ngo-Giang-Huong; Francis Barin; Sophie Le Coeur
Journal:  J Trop Med       Date:  2010-08-17

2.  Nanoplasmonic quantitative detection of intact viruses from unprocessed whole blood.

Authors:  Fatih Inci; Onur Tokel; Shuqi Wang; Umut Atakan Gurkan; Savas Tasoglu; Daniel R Kuritzkes; Utkan Demirci
Journal:  ACS Nano       Date:  2013-05-20       Impact factor: 15.881

Review 3.  Clinical practice treatment of HIV infection in children.

Authors:  Bénédicte Brichard; Dimitri Van der Linden
Journal:  Eur J Pediatr       Date:  2009-01-17       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.